Pathophysiology of pulmonary hypertension for md exams 10 marks answer from fishman and murray only

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Excellent! I now have comprehensive material from both Fishman's Pulmonary Diseases and Murray & Nadel's Textbook of Respiratory Medicine. I have enough content to write a thorough 10-mark answer. Let me now compile this into a structured exam answer.

Pathophysiology of Pulmonary Hypertension

[10 Marks — Based on Fishman's Pulmonary Diseases & Disorders and Murray & Nadel's Textbook of Respiratory Medicine]

Definition and Hemodynamic Criteria

Pulmonary hypertension (PH) is defined as a resting mean pulmonary arterial pressure (mPAP) greater than 25 mm Hg at rest, confirmed by right heart catheterization. It is classified by the WHO into five groups based on etiology and pathophysiologic mechanism (Table 72-1, Fishman):

Group	Mechanism	Example
1 (PAH)	Obliterative/proliferative vasculopathy	Idiopathic, heritable, CTD-associated
2	Pulmonary venous hypertension (passive)	Left heart disease, mitral stenosis
3	Hypoxic vasoconstriction	COPD, ILD, high altitude
4	Thromboembolic obstruction	CTEPH
5	Multifactorial/unclear	Sarcoidosis, metabolic disease

The core pathophysiologic mechanisms, particularly relevant to Group 1 (PAH), operate through four overlapping processes:

1. Imbalance of Vasoactive Mediators (Endothelial Dysfunction)

Fishman, Ch. 72: The development of PAH involves increased pulmonary vascular resistance (PVR) due to sustained vasoconstriction, vascular remodeling, in situ thrombosis, and increased atrial wall stiffness. Abnormalities in the expression of numerous vasoactive mediators, vasoconstriction mediators, growth factors, and cytokines originate in or alter pulmonary arterial endothelial cells (PAECs), pulmonary arterial smooth muscle cells (PASMCs), and platelet function, resulting in a thickened vessel wall with markedly narrowed or obliterated lumen.

Vasodilators are decreased:

Prostacyclin (PGI2): Produced by endothelial cells; potent vasodilator and inhibitor of platelet aggregation. In PAH, prostacyclin synthase expression is markedly reduced. This forms the basis for prostacyclin-analog therapy (epoprostenol, iloprost).
Nitric oxide (NO): Synthesized by endothelial nitric oxide synthase (eNOS); activates soluble guanylate cyclase → cGMP → vasodilation. In PAH, eNOS expression and activity are reduced. Nitration of eNOS (nitrosative stress) is an early contributor. Nitration of protein kinase G (PKG) attenuates vasodilation and increases smooth muscle proliferation. This explains the use of PDE-5 inhibitors (sildenafil, tadalafil), which block cGMP breakdown.

Vasoconstrictors are increased:

Endothelin-1 (ET-1): A potent vasoconstrictor and mitogen produced by endothelial cells. It acts on ET-A receptors (vasoconstriction, proliferation) and ET-B receptors (partial vasodilation via NO release, but also vasoconstriction in smooth muscle). ET-1 levels are markedly elevated in PAH plasma and lung tissue. This is the rationale for endothelin receptor antagonists (bosentan, ambrisentan).
Thromboxane A2: Vasoconstrictor and platelet activator; its ratio to prostacyclin is markedly elevated.
Serotonin (5-HT): Elevated in PAH; promotes PASMC proliferation and vasoconstriction via 5-HT transporter and 5-HT2A receptor.

2. Vascular Remodeling

Fishman, Ch. 72: The thickness and tissue mass of the pulmonary arterial walls are normally maintained by a fine balance between proliferation and apoptosis of fibroblasts, PASMCs, and PAECs. In PAH, this balance is disrupted in favor of cellular proliferation. The resulting structural changes - hypertrophy and/or luminal occlusion - are collectively termed pulmonary vascular remodeling.

Key cellular mechanisms:

PASMC hypertrophy and hyperplasia: Increased PVR and sustained vasoconstriction enhance PASMC hypertrophy and hyperplasia. Extension of smooth muscle into vessels normally only partially muscularized or non-muscularized is a common and prominent feature of precapillary vessels.
Decreased apoptosis: Induction of anti-apoptotic pathways (notably in endothelial cells) permits unchecked proliferation, producing the characteristic "plexiform lesion" - a nest of proliferating, quasi-neoplastic endothelial cells.
Myofibroblast transdifferentiation: Hypoxia induces α-smooth muscle actin expression in adventitial fibroblasts, transforming them into proliferative myofibroblasts.
Intimal fibrosis: Progressive fibrosis of the intima leads to fixed, irreversible narrowing - explaining why pure vasodilators cannot reverse advanced disease.

Ca²⁺ homeostasis is central to both vasoconstriction and remodeling: A rise in cytosolic free Ca²⁺ concentration ([Ca²⁺]cyt) in PASMCs is a major trigger for both vasoconstriction and PASMC proliferation/migration. Resting [Ca²⁺]cyt is elevated in proliferating PASMCs versus growth-arrested cells. Multiple channels contribute - store-operated Ca²⁺ entry (SOCE), receptor-operated Ca²⁺ entry (ROCE), and voltage-dependent Ca²⁺ channels (VDCC).

3. Potassium Channel Dysregulation

Fishman, Ch. 72: Voltage-gated K⁺ (Kv) channel expression is downregulated in PAH (specifically Kv1.5, Kv2.1). Normally, K⁺ efflux via Kv channels keeps the membrane hyperpolarized, which inactivates VDCC and keeps [Ca²⁺]cyt low. In PAH:

Downregulation of Kv channels → membrane depolarization → VDCC activation → increased [Ca²⁺]cyt → vasoconstriction + PASMC proliferation
Kv channels are also required for apoptosis (apoptosis requires K⁺ efflux and cell volume loss); their suppression inhibits apoptosis, enabling unchecked proliferation

4. Genetic and Molecular Mechanisms

Fishman, Ch. 72: BMPR2 mutation (bone morphogenetic protein receptor type 2) is the most important genetic factor, accounting for ~80% of heritable PAH (HPAH) and 11-40% of apparently sporadic IPAH. BMPR2 mutations (predominantly nonsense, frameshift, or splice-site) lead to:

Loss of anti-proliferative, pro-apoptotic BMP signaling in PASMCs
Unopposed growth factor signaling → PASMC proliferation → vascular remodeling

Other genes include: ALK1, endoglin (ENG) - linked to hereditary hemorrhagic telangiectasia; SMAD9, GDF2/BMP9; TBX4 (enriched in children). The low penetrance of BMPR2 mutations (only ~27% of carriers develop disease, female > male) indicates that additional genetic/environmental "second hits" are required.

The vascular changes share features with cancer: somatic mutations, microsatellite instability, aneuploidy, and miRNA dysregulation have all been documented in PAH lung tissue.

5. Oxidative and Nitrosative Stress

Fishman, Ch. 72 (Ch. 28): Increased expression of ROS-generating enzymes (NOX2, NOX4, NOX1), uncoupling of NOS enzymes, and mitochondrial dysfunction all contribute to oxidative stress in PAH.

NOX-derived ROS causes medial thickening, disordered PASMC proliferation and migration, impaired angiogenesis, and disturbed fibrinolysis
Xanthine oxidase (XO) activity is increased in IPAH
Nitration of eNOS, PKG, and carnitine acetyltransferase impairs vasodilation and normal mitochondrial function
TGF-β1 upregulates NOX4 → more ROS → PASMC proliferation and VEGF upregulation

6. In Situ Thrombosis

In PAH, multiple pro-thrombotic factors converge:

Reduced prostacyclin → loss of platelet inhibition
Increased thromboxane A2 → platelet activation
Endothelial injury → exposure of subendothelial collagen → platelet aggregation
Reduced tissue plasminogen activator (tPA) → impaired fibrinolysis

These promote in situ microthrombus formation within small pulmonary arteries, further reducing the vascular lumen and worsening PVR.

7. Right Ventricular Consequences

Fishman, Ch. 72 (Murray, Ch. 84): As PVR rises progressively, the right ventricle (RV) must generate increasingly higher pressures to maintain cardiac output. The sequence is:

RV hypertrophy - initially compensatory (concentric hypertrophy)
RV dilatation - as wall stress increases and contractility fails
Interventricular septal flattening/paradoxical motion - the dilated RV compresses the LV (D-shaped septum on echo), impairing LV filling
Tricuspid regurgitation - from annular dilatation of the dilated RV
RV failure - rising right atrial pressure → hepatomegaly, elevated JVP, peripheral edema, ascites
Decreased cardiac output → reduced systemic oxygen delivery → fatigue, syncope, peripheral cyanosis
Late: right-to-left shunt via patent foramen ovale (PFO) → central cyanosis

Summary Table: Pathogenetic Mechanisms of Pulmonary Hypertension

(Fishman, Table 72-2)

Type	Mechanism	Clinical Example
Passive	Pulmonary venous hypertension	Mitral stenosis, left atrial myxoma
Hyperkinetic	Increased pulmonary blood flow	Left-to-right intracardiac shunts
Obstructive	Thromboembolic disease	Multiple pulmonary emboli, CTEPH
Obliterative	Proliferative vasculopathy	PAH, ILD, schistosomiasis
Venoconstrictive	Hypoxia	COPD, high altitude
Idiopathic	Unknown	Drug-associated, portopulmonary, HIV-PH

Key Points for the Exam

Endothelial dysfunction is the initiating event in PAH: reduced NO and prostacyclin + excess ET-1 and thromboxane
BMPR2 mutation is the most common genetic cause (~80% HPAH); acts by enabling PASMC proliferation
Ca²⁺ dysregulation in PASMCs drives both vasoconstriction and remodeling
Kv channel downregulation causes membrane depolarization → Ca²⁺ entry → vasoconstriction and anti-apoptosis
Plexiform lesion is the hallmark histopathologic finding of severe PAH - it represents a network of proliferating, apoptosis-resistant endothelial cells
RV failure is the final common pathway of death in PAH
Therapies target the three pathways: endothelin axis (ERAs), NO-cGMP axis (PDE5i, sGC stimulators), and prostacyclin axis (prostanoids)

Sources: Fishman's Pulmonary Diseases and Disorders, 2-Volume Set (9781260473940), Ch. 72 - Pulmonary Arterial Hypertension; Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume Set (9780323655873), Ch. 84 - Pulmonary Arterial Hypertension

This is a shared conversation. Sign in to Orris to start your own chat.